Healthcare
Soleno Therapeutics, Inc.(SLNO)
Live Price
Offline$53.01
+0.00% today
Window Change
-34.89%
Window
Jun 23, 2025 โ May 18, 2026
- Market Cap
- $2.73B
- Revenue Growth
- 0.0%
- EPS Growth
- +109.4%
- Dividend Yield
- 0.0%
Coverage: 227 bars ยท Jun 23, 2025 โ May 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Soleno Therapeutics, Inc. (SLNO) is a Healthcare stock with a market cap of $2.73B and listed on NASDAQ. The stock last traded around $53.01 and down 34.9% across the available one-year price window (Jun 23, 2025 โ May 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +109.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +109.4%, free cash flow +167.4% with operating margin 5.4% and ROIC 2.0%. Valuation already assumes a fairly strong business story at P/E 134.6 and price/sales 14.4. Stock Foundry combines SLNO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
+5.4% vs +19.4% peer median
P/E
Above sector median
134.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +109.4%, while operating margin sits near 5.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +0.0% | +0.0% | โ |
2026 Feb 25, 2026 | +25.0% | -7.1% | -7.0% | -22.4% |
2025 Nov 4, 2025 | +717.4% | -26.6% | -23.7% | -20.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLNO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SLNO Max Drawdown
-66.04%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SLNO and SPY.
Company Overview
Soleno Therapeutics, Inc.
NASDAQ Capital Market
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
- Leadership
- Anish Bhatnagar
- IPO Date
- Nov 13, 2014
- Employees
- 115
- Street Address
- 203 Redwood Shores Parkway
- Mailing
- Redwood City, CA, 94065
- Region
- Redwood City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 213 8444
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 134.6
- EV/EBITDA
- 94.0
- Price/Sales
- 14.4
- Price/Book
- 6.2
Growth
- Revenue
- 0.0%
- EPS
- +109.4%
- Free Cash Flow
- +167.4%
Profitability
- Gross Margin
- 98.6%
- Operating Margin
- 5.4%
- Net Margin
- 11.0%
- ROE
- 5.9%
- ROIC
- 2.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 5.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.